

1 **Tobacco, nicotine, and cannabis use and exposure in an**
2 **Australian Indigenous population during pregnancy: A protocol**
3 **to measure parental and foetal exposure and outcomes.**

4
5

6 Angela Ratsch^{1,2}, Elizabeth A. Burmeister^{1,2}, Aunty Veronica Bird³, Aunty Joyce
7 Bonner³, Uncle Glen Miller^{3,4}, Aunty Marj Speedy³, Graham Douglas⁵, Stevan Ober⁵,
8 Ann Woolcock⁵, Sharly Blair (nee Murdoch)⁵, Min-Tz Weng⁶, Jared A. Miles⁶, Kathryn
9 J. Steadman⁶

10
11

12 ¹Wide Bay Hospital and Health Service, Hervey Bay, Australia

13 ²Rural Clinical School, The University of Queensland, Brisbane, Australia

14 ³Butchulla Aboriginal Corporation, Fraser Coast, Australia

15 ⁴Butchulla Mens Business Association, Fraser Coast, Australia

16 ⁵Galangoor Duwalami Primary Healthcare Service, Fraser Coast, Australia

17 ⁶School of Pharmacy, The University of Queensland, Brisbane, Australia

18

19 *Corresponding author

20 E-mail: angela.ratsch@health.qld.gov.au

21
22

23 **Tobacco, nicotine, and cannabis use and exposure in an**
24 **Australian Indigenous population during pregnancy: A protocol**
25 **to measure parental and foetal exposure and outcomes.**

26 **Abstract**

27 **Background:** The Australian National Perinatal Data Collection collates all live and
28 stillbirths from States and Territories in Australia. In that database, maternal
29 cigarette smoking is noted twice (smoking <20 weeks gestation; smoking >20 weeks
30 gestation). Cannabis use and other forms of nicotine use, for example vaping and
31 nicotine replacement therapy, are not reported. The 2021 report shows the rate of
32 smoking for Australian Indigenous mothers was 42% compared with 11% for
33 Australian non-Indigenous mothers. Evidence shows that Indigenous babies exposed
34 to maternal smoking have a higher rate of adverse outcomes compared to non-
35 Indigenous babies exposed to maternal smoking.

36

37 **Objectives:** The reasons for the differences in health outcome between Indigenous
38 and non-Indigenous pregnancies exposed to tobacco and nicotine is unknown but will
39 be explored in this project through a number of activities. Firstly, the patterns of
40 parental and household tobacco, nicotine and cannabis use and exposure will be
41 mapped during pregnancy. Secondly, a range of biological samples will be collected
42 to enable the first determination of Australian Indigenous people's nicotine and
43 cannabis metabolism during pregnancy; this assessment will be informed by
44 pharmacogenomic analysis. Thirdly, the pharmacokinetic and pharmacogenomic
45 findings will be considered against maternal, placental, foetal and neonatal outcomes.

46 Lastly, an assessment of population health literacy and risk perception related to
47 tobacco, nicotine and cannabis products peri-pregnancy will be undertaken.

48

49 **Methods:** This is a community-driven, co-designed, prospective, mixed-method
50 observational study with regional Queensland parents expecting an Australian
51 Indigenous baby and their close house-hold contacts during the peri-gestational
52 period. The research utilises a multi-pronged and multi-disciplinary approach to
53 explore interlinked objectives.

54

55 **Results:** A sample of 80 mothers expecting an Australian Indigenous baby will be
56 recruited. This sample size will allow estimation of at least 90% sensitivity and
57 specificity for the screening tool which maps the patterns of tobacco and nicotine use
58 and exposure versus urinary cotinine with 95% CI within $\pm 7\%$ of the point estimate.
59 The sample size required for other aspects of the research is less (pharmacokinetic
60 and genomic $n=50$, and the placental aspects $n=40$), however from all 80 mothers, all
61 samples will be collected.

62

63 **Conclusions:** Results will be reported using the STROBE guidelines for observational
64 studies.

65

66 **Keywords:** Tobacco; nicotine; cannabis; exposure; pregnancy, pregnancy outcomes;
67 Aboriginal and Torres Strait Islander; Australian Indigenous.

68

69 **Forward**

70 *We acknowledge the Traditional Custodians, the Butchulla people, of the lands and*
71 *waters upon which this research is conducted. We acknowledge their continuing*
72 *connections to country and pay our respects to Elders past, present and emerging.*

73

74 Notation: In this document, the terms Aboriginal and Torres Strait Islander and
75 Indigenous are used interchangeably for Australia's First Nations People. No
76 disrespect is intended, and we acknowledge the rich cultural diversity of the groups
77 of peoples that are the Traditional Custodians of the land with which they identify
78 and with whom they share a connection and ancestry.

79 **Introduction**

80

81 In 1957, Simpson [1] reported a dose-response association between maternal
82 smoking and premature birth. This observation resulted in a world-wide research
83 agenda focusing on the impact of maternal smoking in pregnancy, the findings of
84 which indicate that maternal tobacco smoking, and exposure to the products of
85 tobacco combustion (i.e., secondhand smoke exposure) are the leading modifiable
86 risk behaviours associated with adverse maternal and neonatal outcomes. Maternal
87 exposure increases the risk for miscarriage, ectopic pregnancy, antepartum bleeding,
88 placental abruption, placenta previa, postpartum haemorrhage and alters maternal
89 thyroid function [2, 3]. Counterintuitively, smoking in pregnancy is associated with
90 decreased hypertensive disorders of pregnancy [4, 5]. For the foetus, maternal

91 exposure increases the risk of stillbirth, premature birth and lower birthweight [6] as
92 well as increases the risk for a number of congenital abnormalities [7, 8]. Longer-
93 term, offspring exposed in-utero to maternal smoking have decreased cognitive
94 achievement [9] and an increased risk for the development of attention-
95 deficit/hyperactivity disorder (ADHD) [10].

96

97 In Australia, these adverse pregnancy and foetal findings have ensured a prenatal
98 focus on maternal smoking behaviour with the mother's cigarette smoking status
99 obtained during antenatal assessment and recorded in the National Perinatal Data
100 Collection [11] twice across the nine months of pregnancy (once < 20 weeks
101 gestation, and once >20 weeks gestation). In that database, the 2021 rate of smoking
102 by Australian non-Indigenous expectant mothers was reported as 11% compared
103 with 42% by Australian Indigenous expectant mothers [12]. However, the maternal
104 use of other tobacco and nicotine products including e-cigarettes, hookahs, chop-chop
105 tobacco, nicotine tooth cleaning powder, chewing tobacco, and nicotine spray, mist,
106 lozenges, gum and patches, and cannabis is not collected. In addition, this focus on
107 maternal cigarette smoking fails to recognise second- and third-hand maternal
108 nicotine vape and tobacco and cannabis smoke exposure, i.e., the impact from
109 paternal and household tobacco, nicotine and cannabis exposure on maternal and
110 foetal outcomes is overlooked.

111 This assessment gap results in maternal and foetal tobacco, nicotine and cannabis
112 exposure misclassification and ramifications in the planning of care, and in the
113 estimation of adverse maternal, placental, foetal and neonatal outcomes from

114 tobacco, nicotine and cannabis exposure. Nevertheless, the literature indicates that
115 Indigenous babies exposed to maternal smoking have a higher rate of adverse
116 outcomes compared to non-Indigenous babies exposed to maternal smoking, for
117 example, after adjusting for maternal age and other factors, smoking in pregnancy is
118 attributable to 22% of pre-term Indigenous births compared with 5% for non-
119 Indigenous births [13]. Gestational age impacts birthweight, and for Indigenous
120 mothers who smoked in the first 20 weeks of pregnancy, the risk of a lower
121 birthweight baby was 1.8 (or about 80% higher risk) than among Indigenous mothers
122 who did not smoke in the first 20 weeks. For non-Indigenous mothers who smoked
123 in pregnancy, this risk was 1.3 (or 30% higher risk) [14].

124 The other significant foetal outcome attributable to maternal smoking is stillbirth. In
125 Australia, stillbirth is defined as foetal death prior to birth of the baby at 20 weeks
126 gestation or more, and/or weighing 400 grams or more [15]. In 2020, the overall
127 Australian stillbirth rate was 7.7/1000 births, with the rate for Indigenous mothers
128 being 11.9/1000 compared with 7.4/1000 for non-Indigenous mothers. Smoking in
129 pregnancy is a risk factor for stillbirth; for women who smoked in pregnancy, the
130 stillbirth rate was 12.8 stillbirths/1000 births compared to 6.9 stillbirths/1000 births
131 for mothers who did not smoke [15]. Sub-category analysis of smoking and stillbirth
132 for Indigenous mothers compared to non-Indigenous mothers is not published.

133

134 The reasons for the differences in pregnancy outcome between Indigenous and non-
135 Indigenous pregnancies exposed to tobacco and nicotine are unknown but will be
136 explored in this project through a number of activities.

137 **Background**

138 **Nicotine: pregnancy health and the developing human**

139

140 Currently, tobacco assessment in pregnancy is focused on ‘smoking’. This emphasis
141 overlooks the absorption of the pharmacologically active, dose-dependent,
142 potentially lethal component of tobacco-which is nicotine-from other sources [16].
143 This study is premised on some of the actions of nicotine. In brief, nicotine binds with
144 and activates nicotinic acetylcholine receptors (nAChR) in central and peripheral
145 neuronal and non-neuronal tissue, at neuromuscular junctions, and in the adrenal
146 medulla [17]. Receptor type and individual variability, including genetics and
147 pregnancy, result in receptor up-regulation or desensitization [16, 18] and the release
148 of neurotransmitters including acetylcholine, norepinephrine, dopamine, serotonin,
149 vasopressin, beta-endorphin and adreno-corticotrophic-hormone, thus impacting the
150 vasculature and producing vasoconstriction, increasing heart rate and blood pressure
151 [19].

152

153 In pregnancy, nicotine acts both directly on nAChRs in the developing placenta,
154 reducing the number of nAChR receptors [20], and alters placental morphology and
155 vascularity [21]. Nicotine also readily crosses the placenta and stimulates nAChRs in
156 the developing foetus impacting foetal systems, albeit in an immature physiology
157 [22]. During early foetal development (4-6 weeks of gestation), nAChRs emerge and
158 begin to form connections throughout the body including the brain [23], with

159 construction of axons and synaptic connections in the brain continuing after birth
160 into childhood, adolescence and young adulthood [24]. In the foetal brain, nicotine
161 exposure results in accelerated cell development relative to tissue and organ age, that
162 is, there are fewer cells correctly developed for their stage and age [25]. Following
163 nicotine exposure, changes in nAChRs and neural plasticity result in both a deficit in
164 the number of neurons in the foetal brain and synaptic level damage to the
165 respiratory center, with equivalent damage to the adrenal glands [26]. Foetal
166 nicotine exposure ultimately results in a dampened response to hypoxic episodes
167 [27]. These physiological changes are important in understanding links between
168 maternal nicotine exposure and foetal outcomes, for example, stillbirth and Sudden
169 Infant Death Syndrome (SIDS).

170 **Nicotine metabolism and excretion**

171
172 Nicotine has a half-life of about two hours and is metabolised via the CYP2A6 pathway
173 primarily in the liver, with the brain, kidneys and lungs providing minor sites [28].
174 This short half-life produces large nicotine serum plasma fluctuations and poses
175 challenges for intra- and inter-person comparisons of exposure, consumption and
176 effect. However, cotinine (the main tobacco and nicotine metabolite) has a half-life of
177 approximately 17 hours and serum concentrations 10-fold higher than nicotine,
178 providing a more stable biomarker of tobacco and nicotine exposure [29]. Cotinine
179 begins to metabolise after approximately 16 hours into trans-3'-hydroxycotinine (3-
180 OH-cotinine), nornicotine, nicotine glucuronide and nicotine-N-oxide [18]. A more

181 accurate assessment of tobacco and nicotine exposure is achieved by measuring
182 serum tobacco and nicotine and metabolite concentrations (total nicotine equivalents
183 – TNE), as opposed to measuring only nicotine concentration [30].

184

185 During pregnancy, nicotine metabolism is impacted both by individual variability
186 [16] and the changes created by pregnancy. In the expectant mother, there is a
187 significant induction of CYP2A6 activity which increases plasma clearances of
188 nicotine by 60% and cotinine by 140%, in addition, there is an almost 50% reduction
189 in cotinine half-life (down from 17 hours to 9 hours [31]). This is important in the
190 consideration of tobacco and nicotine use in pregnancy as decreases in nicotine and
191 cotinine measurements in late pregnancy compared with pre-pregnancy or early
192 pregnancy may not necessarily indicate a decrease in tobacco and nicotine exposure,
193 but rather the more rapid metabolism of nicotine [32]. In the foetus and neonate, the
194 immature and undeveloped CYP2A6 pathway decreases their ability to metabolise
195 nicotine and results in a much longer plasma nicotine half-life than adults (11.2 hours
196 compared to 2 hours) whereas cotinine elimination is similar to that of adults (16.3
197 hour half-life compared with 17 hours) [33].

198

199 CYP2A6, the major nicotine-oxidising enzyme, is measurable using the nicotine
200 metabolite ratio (NMR; 3' hydroxycotinine:cotinine) and is a biomarker of nicotine
201 clearance [16]. However, NMR is highly heritable (~80%) varying with ethnicity, in
202 part due to CYP2A6 variants. Variation in CYP2A6 genes has not been characterised

203 in Australian Indigenous populations and may contribute to increased/decreased
204 pregnancy risk from tobacco and nicotine exposure.

205

206 Tobacco, nicotine and the metabolites are rapidly excreted by the kidneys with the
207 rate dependent upon urinary pH, where increased urine alkalinity decreases
208 excretion [34]. Urinary excretion is further impacted in pregnancy due to elevated
209 creatinine potentially leading to fluctuations in nicotine and its metabolites [35].
210 Thus, serum provides a measure of exposure and the recency of that exposure, while
211 urine analysis provides a measure of tobacco and nicotine metabolism and excretion.

212 **Materials and Methods**

213 **Aim and Objectives**

214

215 The aim of this study is to develop a foundation from which approaches to tobacco
216 and nicotine assessment, health literacy, tobacco and nicotine cessation, and
217 maternal and neonatal health care delivery for families expecting an Australian
218 Indigenous baby is informed by contemporary evidence. Community input on the
219 design suggested that cannabis use (with and without tobacco) is also prevalent and
220 continues throughout pregnancy, thus cannabis use and exposure have been
221 included.

222

223

224

225 The objectives are to:

- 226 1. Accurately describe parental and close household contact(s) peri-gestational
227 patterns of use and exposure of tobacco, nicotine and cannabis products
228 through the creation and use of a validated assessment tool.
- 229 2. Determine the pharmacokinetic and pharmacogenomic impacts and outcomes
230 of tobacco, nicotine and cannabis exposure. This study will be the first to
231 establish the metabolism of tobacco, nicotine and cannabis during pregnancy
232 by using NMR as a biomarker of individual differences in nicotine and cannabis
233 metabolism in a parental Australian Indigenous population.
- 234 3. Describe maternal, paternal, placental, foetal and neonatal outcomes
235 according to the use and exposure to tobacco, nicotine and cannabis products
236 and biochemical and genomic analysis.
- 237 4. Describe the influences and barriers to cessation for pregnant Australian
238 Indigenous families or close household contacts to reduce or cease tobacco,
239 nicotine and/or cannabis use in pregnancy.

240

241 **Research Governance**

242 This project is centred around the local Australian Indigenous population in the
243 Fraser Coast area (Queensland, Australia). The research will be conducted primarily
244 from Galangoor Duwalami Primary Healthcare Service (the local Aboriginal and
245 Torres Strait Islander Primary Health Service in Hervey Bay and Maryborough) and

246 at the Hervey Bay and Maryborough Hospitals within the Wide Bay Hospital and
247 Health Service (WBHHS).

248

249 Galangoor Duwalami Primary Healthcare Service were consulted in regard to which
250 Community members would best represent the Traditional Owners of the land where
251 this research is to be conducted. A combined leadership group was formed which
252 included the Butchulla Aboriginal Corporation and Butchulla Men's Business
253 Association and this group advised, directed and oversaw the conversations around
254 this research from its inception and arranged for discussions with the appropriate
255 Community members. Under the Butchulla Aboriginal Corporation's Rule Book, the
256 principal Objective of the corporation is to: 'Relieve poverty and disadvantage of the
257 Butchulla People through the advancement of education, health, social or public
258 welfare, and culture'. Accordingly, the Elders have approved this proposal and
259 provided a Butchulla name for the project – *Ngabang* (mother), *Walbai* (baby), *Babun*
260 (father). The project logo (Figure 1) reflects the aspirations of the Butchulla people
261 for this project, which are to strive for a *healthy pregnancy*, which results in a *healthy*
262 *family*, which maintains a *healthy culture*.

263

264

265 *Figure 1 Project logo*

266 The logo also recognises the governance of the project by the Butchulla people,

267 Galangoor Duwalami Primary Healthcare Service, the various Australian research

268 guidelines, and the collaborative nature of the project with other health providers
269 and research-intensive organisations and academic partners. The project
270 documentation, and staff and participant shirts and onesies carry this logo (Figure 2
271 and 3)

272

273 *Figure 2 Participant shirt*

274 *Figure 3 Participant onesie*

275 **Research context**

276 Galangoor Duwalami Primary Healthcare Service generally maintain the sole care of
277 the pregnant women until approximately 20 weeks gestation (unless they have a
278 high-risk pregnancy). The mother then moves to a shared care model with the Hervey
279 Bay and Maryborough Hospitals. In this project, data is collected across the entire
280 pregnancy. The preferred site of data collection from Galangoor Duwalami Primary
281 Healthcare Service patients will be at Galangoor Duwalami Primary Healthcare
282 Service for as long as possible during the pregnancy, however some data collection
283 will need to occur at antenatal visits at the Hervey Bay or Maryborough Hospitals. At
284 birth (mostly likely at the Hervey Bay Hospital), biological samples will be collected,
285 and birthing data will be collected on the participant's discharge from hospital.

286 **Inclusion and exclusion criteria and consent**

287 Potential participants who meet the following criteria will be invited to enrol in the
288 study: pregnant mothers, aged 15 years or older at the time of enrollment, able to

289 understand English, able to provide informed consent, and who self-identify as being
290 pregnant with an Australian Indigenous baby. In accordance with the value of Respect
291 outlined in the National Statement of Ethical Conduct in Human Research [36], all
292 potential maternal participants meeting the inclusion criteria will be carefully
293 considered by the clinic midwife or healthcare medical officer to ensure the
294 healthcare staff believe that potential enrolment is in the best interest of the
295 participant at this point in their pregnancy. A list of suitable potential maternal
296 participants will then be provided to the researchers; only those participants will be
297 provided with research information.

298

299 The project will strive to enrol the family unit i.e., the mother, and the foetus, and the
300 biological father, or non-biological parent partner (the parents), or one close
301 household contact. For example, if an expectant mother lives with her sister or aunty
302 or grandmother but there is no biological father in the family at that time, or there is
303 a partner (of either gender) and that close family contact attends the antenatal visits
304 with the maternal participant, that person will be invited to participate with the
305 expectant mother. Family members do not have to participate; however, 'family' is
306 central to Australian Indigenous people, and enrolling participants who constitute the
307 cultural norm of family will be especially important in the translation of findings to
308 the participant and the community.

309

310 Consent: Participants can choose to enrol in any or all aspects of the data and sample
311 collection, and they can withdraw from any or all aspects of the research at any time.

312 The consent process enables participants to choose to have their individual results
313 provided back to them at the completion of the project; for any or all samples to
314 returned to the participant on completion of this project; or for the de-identified
315 samples and de-identified data to be retained for ethically approved un-identified
316 projects in the future. All enrolled participants will receive a participant shirt (Figure
317 2), and liveborn newborns will receive a project onesie (Figure 3).

318

319 A subset of information-rich tobacco, nicotine and/or cannabis use/exposed
320 participants will be enrolled into the separate male and female qualitative aspects of
321 the study until saturation is reached (~30 participants). Data will be collected in
322 response to a range of trigger questions and survey questions. Participants enrolled
323 in the qualitative data collection will receive a \$50 grocery voucher in
324 acknowledgement of their time to the project.

325

326 ***Tobacco, nicotine and cannabis use and exposure data and biological sample collection***

327 The quantitative data and sample collection for Objectives 1-3 is designed to
328 measure maternal tobacco, nicotine and cannabis use, and maternal and foetal
329 exposure, metabolism and excretion at varying times throughout the pregnancy and
330 assess the findings against the maternal and foetal outcomes. At each antenatal
331 appointment and at birth, tobacco, nicotine and cannabis use and exposure
332 information will collected on a *NicOTIne, tobacco, and Cannabis use and Exposure*
333 *(NOTICE) Assessment Tool* (Figure 4 and see Box 1 NOTICE Notes).

334

335 *Figure 4 NOTICE: NicOTIne, tobacco, and Cannabis use and Exposure (NOTICE)*

336 Assessment Tool

337

338 **Box 1. NicOTIne tobacco, and Cannabis use and Exposure (NOTICE)**

339 **Assessment Tool – Notes.**

The NicOTIne tobacco, and Cannabis use and Exposure (NOTICE) assessment tool (Figure 4) has been developed by Angela Ratsch for this study to enable a comprehensive assessment of the use of smoked and smokeless tobacco and cannabis products as well as nicotine containing products. The tool also allows for the detailing of second-hand exposure, and is used in this protocol to inform the use and exposure of all products throughout the pregnancy. The recorded information facilitates a scoring method to determine the level of self-reported use and exposure to tobacco, nicotine and cannabis products (scored for the day of assessment, previous 24 hours, and the previous week).

A self-use weekly score will be calculated for each assessment completed. Scoring for self-use will be categorized for each product as: 0 - no use; 1 – low use (1 to 70 combusted or inhaled products); 2 – medium use (71-140 combusted or inhaled products); 3 – high use (141 + combusted or inhaled products). A self-use score will be calculated for each weekly product combusted or inhaled with the sum of these scores producing a total weekly self-use score with a range of 0-30. An exposure score will be calculated for each weekly product exposed to by multiplying the quantity exposed to score by the exposure. Exposure is categorized as 0 - no exposure; 1- some

limited exposure; 2 - moderate exposure or 3 - unrestricted exposure. A total weekly exposure score is then calculated by summing all the exposure scores with a range of 0-99 for each assessment completed.

The assessment takes about 3 minutes to complete and will be conducted at each antenatal visit and immediately prior to birth.

Exhaled breathe carbon monoxide (CO) assessment

CO as a point of care (POC) assessment provides indicative information about combusted tobacco/cannabis use up to 24 hours previously. Exhaled CO monitors (Smokerlyser®) provide a CO ppm reading ranging between 0 and 30 and a percentage of oxygen replaced with CO on haemoglobin (%COHb) with higher readings indicating higher levels of combusted tobacco/cannabis use. The same device can measure foetal exposure as foetal carboxyhaemoglobin (%FCOHb). Readings for the level of CO ppm are categorized as:

- green—for no and general environmental combusted tobacco/cannabis exposure, indicated by CO <3 ppm for pregnant women, and CO <6 ppm for non-pregnant adults;
- orange—moderate combusted tobacco/cannabis exposure, indicated by CO 4-6 ppm for pregnant women, and CO 7-10 ppm in non-pregnant adults and;
- red—heavy combusted tobacco/cannabis exposure, indicated by CO >6 ppm for pregnant women, and CO >10 ppm in non-pregnant adults.

The assessment takes about 1 minute to complete and will be conducted at each antenatal visit and immediately prior to birth.

Saliva cotinine assessment

The use of non-combusted tobacco products and nicotine substances, for example, chewed tobacco, e-cigarettes, nicotine patches and gum, does not create CO. Instead, cotinine saliva assessment (Oz Drug Tests®), as a POC measurement, can detect cotinine (the major metabolite of nicotine metabolism). The test has a cotinine cut-off value of 10 ng/mL and the expected window of detection for cotinine in saliva at 10 ng/mL is expected to be up to 2-3 days after the last nicotine use. The assessment takes about 3 minutes to complete and will be conducted at each antenatal visit and immediately prior to birth.

Procedure: The CO assessment will be conducted first, and if the CO level is within the yellow or red zone (high levels), a saliva test will not be conducted as these CO levels are indicative of combusted tobacco use and negates the requirement for saliva testing.

340

341 ***Sample collection process***

342 *Mother*

343 At the first antenatal appointment, maternal urine, CO and saliva samples will be
344 collected on a NOTICE Tool.

345 If the CO is within the orange or red zones, a cotinine saliva test will not be
346 conducted. Also, during this first appointment, or when maternal bloods are being
347 collected as part of standard care, maternal vein blood will be collected for this
348 project.

- 349 • At each follow-up antenatal visit, maternal urine, CO and saliva (if indicated) will
350 be collected and a NOTICE assessment completed.

351 *Biological father*

- 352 • At the first antenatal appointment, if the biological father is Indigenous, paternal
353 vein blood, urine and semen will be collected and CO, saliva (if indicated), and a
354 NOTICE assessment completed.

- 355 • At each follow-up visit, the biologically paternal CO and saliva (if indicated)
356 samples will be measured and a NOTICE assessment completed.

357 *Non-biological parent, partner or close household member*

- 358 • At the first antenatal visit, the non-biological parent partner or close household
359 contact will have a CO and saliva (if indicated) measured and a NOTICE
360 assessment completed and these same tests will be conducted at each visit.

361 *Unaccompanied mother*

- 362 • If the biological father, partner or household member is not present, the expectant
363 mother will report her exposure to the partner's and/or household member's
364 combusted tobacco or heated nicotine (e-cigarette) as second-hand exposure on
365 the NOTICE assessment tool.

366 *At birth*

- 367 • On presentation for birth, mothers will have a venous blood sample, urine, CO and
368 saliva samples (if indicated) collected and a NOTICE assessment will be
369 completed.
- 370 • At spontaneous or artificial rupture of membranes or caesarean birth, amniotic
371 fluid will be collected.

- 372 • Following birth and the separation of the placenta from the mother and neonate,
373 arterial and venous cord bloods will be collected from the placenta.
- 374 • The placenta will be weighed in grams, and measured in centimetres at two points,
375 the widest and narrowest to estimate the area of the placenta. Placental
376 photographs of the maternal and foetal side and the cord will be obtained.
- 377 • Placental samples for macro, micro-morphological and genomic examination will
378 be obtained, rinsed in a solution of phosphate buffered saline and distilled water
379 and then placed in a solution of RNA later. The placenta sent for standard
380 histology.

381 *Postnatal*

- 382 • Following birth, neonates will have a Day 0-1 urine and meconium collected. If
383 the neonate remains in hospital after Day 1, a further urine sample will be
384 collected. The urine will be collected with the use of a standard adhesive urine
385 collection device, and meconium will be collected from the nappy.
- 386 • Colostrum/breast milk will be collected when available. As active participants in
387 the knowledge generation from this research, mothers will be encouraged to
388 obtain their own colostrum/breast milk sample by hand/pump expression.

389 ***Clinical information***

390 Data contained in the Galangoor Duwalami Primary Healthcare Service and Hospital
391 record including demographic, maternal, and neonatal data will be included in the
392 research database. Pregnancy, labour and birthing information will be collected from
393 the Queensland Health Perinatal Record following birth.

394 **Biological sample analysis.**

395 After labelling, participant samples will be stored in the appropriate solution and/or
396 temperature control manner. Placental samples in RNA later will be transferred to
397 the University of the Sunshine Coast for storage at -80°C. Other samples (excluding
398 the whole placenta in formalin) will be transferred to the local Sullivan and Nicolaides
399 Pathology at standard intervals. Sullivan and Nicolaides will then transfer directly to
400 The University of Queensland for storage at -80°C. The placenta in formalin will be
401 transferred to Queensland Pathology. The scientists undertaking the biological
402 examinations and analysis will be blinded to the self-reported tobacco, nicotine and
403 cannabis status of the participant.

404 Pregnancy elevates creatinine levels, potentially leading to fluctuations in the levels
405 of nicotine and its metabolites and influencing cannabinoid levels [35]. To ensure the
406 standardisation of these levels in urine samples during pregnancy, a creatinine
407 analysis will be conducted. The biological samples will be initially analysed for
408 tobacco, nicotine and their metabolites and cannabinoid concentration in ng/mg
409 creatinine or nmol/mg creatinine for urine samples and ng/mL for other biological
410 samples using standard procedures. Following this, the samples will undergo
411 tobacco, nicotine and cannabinoid genomic assessment in relation to tobacco,
412 nicotine and cannabis pharmacokinetics, and other examinations including thyroid
413 antibodies, transthyretin and sENG levels and a genomic-wide analysis of tobacco
414 nicotine and cannabis induced alterations will be conducted. In addition, the
415 colostrum/breast milk microbiome will be considered for the impact of tobacco,
416 nicotine and cannabis exposure.

417 ***Qualitative data collection***

418 Information-rich participants will be invited to take part in a face-to-face interview
419 and survey. The interview and survey will be in the form of a yarn [37-39] which will
420 be conducted at a place of the participants choosing and audio recorded for review.
421 Participants are welcome to have support people with them should they wish. Data
422 will be responses to a range of trigger questions and survey questions to consider the
423 barriers and influences to tobacco, nicotine and cannabis use and cessation, and to
424 understand the population's health literacy and risk perception related to tobacco,
425 nicotine and cannabis products peri-pregnancy. Participant's own language and slang
426 will be used when possible. Data will be collected in a coded, but re-identifiable
427 manner to enable researcher and participant follow-up. The code that will be used
428 will be the same as for the participant's biological and clinical data collection. The
429 codebook will be kept in a separate location to the recording. During the interviews,
430 the participant will only be identified by the unique code.

431 **Outcome assessment**

432 Enrollment maternal blood and urine samples provide a baseline and are correlated
433 to exhaled carbon monoxide (CO), cotinine saliva assessment, and the self-reported
434 tobacco, nicotine and cannabis assessment tool (see Figure 4 and Notes: Table 1).
435 At each antenatal visit, maternal urine is collected and correlated to the CO and saliva
436 assessment and the self-reported tobacco, nicotine and cannabis assessment tool. At
437 birth, a second maternal blood is taken to correlate to the excretion of nicotine and
438 cannabis by the mother and neonate as measured in maternal and neonatal urine,

439 breast milk and meconium. The transfer of nicotine and cannabis to the fetus
440 through the placenta and return to the mother is measured by amniotic fluid, arterial
441 and venous cord blood, and placenta samples.

442

443 Outcomes include:

444 1. Parental and close household member's patterns of self-reported use and
445 exposure to tobacco, nicotine and cannabis using the NOTICE Tool score. Total self-
446 use and total exposure scores will be calculated by summing the total weekly quantity
447 and exposure scores. Scores will then be categorised into clinically meaningful
448 categories, with those reporting no exposure or use categorised as the reference
449 group.

450 2. Tobacco, nicotine, cannabis and their metabolites concentration in ng/ml or
451 nmol/ml. Concentrations of tobacco, nicotine, trans-3'-hydroxycotinine (3-OH-
452 cotinine), nornicotine, nicotine glucuronide and nicotine N oxide, norcotinine, NNAL,
453 nicotelline, anabasine and anatabine [40, 41] will be summed with the total
454 concentration in each sample recorded as total nicotine equivalents (TNE) and the
455 nicotine metabolite ratio (NMR: 3'-hydroxycotinine/cotinine) will be calculated [42].
456 Similarly, delta-9-tetrahydrocannabinol-D3 (THC-D3) and delta-8 and/or delta-9
457 carboxy tetrahydrocannabinol-D3 (THC-COOH-D3) will be measured and summed.

458 3. DNA methylation patterns influenced by tobacco, nicotine and cannabis use
459 and exposure will be identified. Methylation levels will be assessed either by
460 immunohistological analysis of methylation intermediates (5mC, 5-hmC) or
461 calculated and expressed as β values (β = intensity of the methylated allele (M))/

462 (Intensity of the unmethylated allele (U) + intensity of the methylated allele (M) +
463 100).

464 4. Specific tobacco, nicotine and cannabis induced genomic and DNA alterations
465 related to the use and exposure tobacco, nicotine and cannabis products in the
466 different participant groups (maternal, paternal, foetal placental and neonatal).
467 Genotypes influenced by tobacco, nicotine and cannabis use and exposure will be
468 identified. Genome-wide mRNA profiles will be sequenced and expressed as read
469 counts per mRNA.

470 5. Identified genes and alternations (including gene expression) associated with
471 tobacco, nicotine and cannabis metabolism and pregnancy clinical outcomes. Genes,
472 including CYP2A6 and TCF7L2, with single nucleotide polymorphisms (SNPs) with
473 minor allele frequency greater than 10% will be chosen for inclusion in analyses. PCR
474 results will be reported as negative or positive.

475 6. Semen volume (mL) and quality including sperm concentrations (million per
476 mL), count (million), progressive motility (%), vitality (%), morphology (%), pH (0-
477 14), leucocyte counts (millions per mL).

478 7. CO readings will be used as continuous scores and also categorised as: 1)
479 negligible combusted tobacco/cannabis exposure - indicated by <6 CO ppm for non-
480 pregnant adults and <3 CO ppm for pregnant women; 2) light combusted
481 tobacco/cannabis exposure - indicated by 7-10 CO ppm in non-pregnant adults and
482 4-6 CO ppm for pregnant women; 3) heavy combusted tobacco/cannabis exposure -
483 indicated by >10 CO ppm in non-pregnant adults and >6 CO ppm in pregnant women.

484 8. Saliva readings will be used as dichotomous scores, categorised as negative or
485 positive

486 9. Maternal and neonatal outcomes including miscarriage, livebirth/stillbirth,
487 gestational age (weeks), preterm birth (<37 weeks gestation), and birth weight
488 (grams), pregnancy induced hypertension and pre-eclampsia, gestational diabetes,
489 thyroid autoimmune disease, maternal anaemia and other factors of interest are
490 listed in Supplementary Table 1.

491 ***Sample size***

492 Approximately 80 women expecting an Indigenous baby attend antenatal care at
493 Galangoor Duwalami Primary Healthcare Service and the Hervey Bay and
494 Maryborough Hospitals each year, and birth at the Hervey Bay Hospital.

495

496 Sample size to validate the NOTICE tool: To estimate the sensitivity and specificity of
497 the NOTICE self-reported assessment tool for tobacco and nicotine use and exposure,
498 assuming tobacco and nicotine exposure and use of 66% [43], a sample of 80 mothers
499 with 5 or more assessments would allow estimation of at least 90% sensitivity and
500 specificity for the screening tool for tobacco and nicotine use and exposure versus
501 urinary cotinine with 95% CI within $\pm 7\%$ of the point estimate [44]. The collection
502 and validation of the additional tobacco and nicotine products increases both the
503 sensitivity and specificity of the tool. Validation will be to POC CO, saliva cotinine, and
504 blood and urine total nicotine equivalents [40, 41]. The collection of cannabis use and

505 exposure measured against urinary cannabinoid concentrations provides an
506 assessment of the tool's broader utility in pregnancy.

507

508 Using multilevel linear regression modelling with urinary cotinine levels as an
509 outcome and adjusted for tobacco and nicotine use and exposure, to estimate a
510 statistically significant change in tobacco and nicotine metabolism during pregnancy
511 in an Australian Aboriginal population, with a power of 80% and alpha level of 0.05,
512 a total of 50 mothers would be required to have a minimum of five tobacco and
513 nicotine urine measurements during pregnancy [45] assuming an intra-class
514 correlation of 0.3 (or lower) between urinary cotinine levels for each mother during
515 pregnancy. With a power of 80% and alpha level of 0.05, 34 placentas would be
516 required to be examined to estimate a 50 cm² difference in area between high and
517 low tobacco and nicotine use/exposure.

518 ***Data analysis***

519 Following data cleaning, checking and validation, the participants' results from the
520 NOTICE scores for tobacco, nicotine and cannabis use and exposure, the biochemical
521 analysis from all biochemical samples, and the maternal and neonatal outcomes will
522 be examined to address the research objectives as described in Table 1. All data
523 analysis will be conducted using Stata 17 (Statacorp, Texas). Missing data and outliers
524 will be examined and reported. Results will be reported with 95% confidence
525 intervals (95% CI) and statistical significance at alpha 0.05.

526

Table 1 Research outcomes and statistical analysis

<p>Objective 1: To accurately describe parental and close household contact(s) peri-gestational patterns of use and exposure to tobacco, nicotine and cannabis products through the creation and use of a validated assessment tool.</p>	
<p>Outcomes</p>	<p>Statistical analysis</p>
<p>a) Record parental and close house-hold member’s patterns of self-reported use and exposure to tobacco, nicotine and cannabis using the NOTICE tool.</p>	<p>a) Descriptive statistics of tobacco, nicotine and cannabis use and exposure self-reported assessment scores will be reported including frequency, means/medians and percentages. The score will be used as a continuous and/or ordinal categorical variable in analyses.</p>
<p>b) Conduct biochemical analysis of parental and neonatal samples for tobacco, nicotine and cannabis and metabolites.</p>	<p>b) Descriptive statistics of tobacco, nicotine and cannabis and metabolites levels from collected samples will be reported including frequency, means/medians and percentages. The levels will be used as a continuous and/or ordinal categorical variable in analyses. Participants will be categorised into faster or slower metabolism groups based on their plasma NMR, which is considered the most reliable measure [32, 46]. To ensure the normalization of distribution between the two groups, log-transformed NMR values will be used. In this study, log urine NMR will be utilized across three trimesters of pregnancy, serving as a non-invasive alternative to plasma NMR values. The association between plasma NMR and other NMR values obtained from other biological matrices will be investigated. Two groups (fast and slow metabolisers) will be compared based on their tobacco and nicotine use and exposure behaviours (e.g., cigarettes per day) and TNE levels from maternal urine samples. To assess nicotine exposure in newborn infants, TNE will be calculated for various biological samples including neonate urine, meconium, amniotic fluid, breast milk, and neonate blood samples. A Welch t-test analysis will be used to determine statistically significant differences between the two groups based on their NMR values. Additionally, a regression model will be utilized to present the association between NMR values using different biological matrices. The relationship between plasma NMR values, smoking behaviors, nicotine exposure on newborn babies, and TNE levels will be analysed using a regression model.</p>

<p>c) Compare maternal self-reported use and exposure with biochemical assessment of tobacco, nicotine and cannabis concentrations to establish the specificity, sensitivity and predictive validity of the NOTICE tool.</p>	<p>c) The sensitivity, specificity and predictive validity of the screening tool for tobacco, nicotine and cannabis use and exposure will be estimated by comparing self-reported scores with recorded cotinine saliva and CO levels at each antenatal visit.</p> <p>Reliability of the NOTICE tool will also be evaluated using linear regression with urinary nicotine, tobacco and metabolite levels as the outcome and the predictive value of the self-reported scores estimated.</p>
<p>Objective 2: To determine the pharmacokinetic and pharmacogenomic impacts and outcomes of tobacco, nicotine and cannabis exposure.</p>	
<p>Outcomes</p>	<p>Data and Statistical analysis</p>
<p>a) Investigate specific tobacco, nicotine and cannabis-induced maternal, paternal, foetal, placental and neonatal genomic alternations related to the use and exposure to tobacco, nicotine and cannabis products.</p> <p>b) Determine tobacco, nicotine and cannabis metabolism by genotype (pharmacogenomics).</p> <p>c) Establish the pharmacokinetics of tobacco, nicotine and cannabis in this population.</p>	<p>a, b, c) Descriptive statistics will be used to report the frequency and proportion of participants with identified genetic factors related to the use of tobacco, nicotine and cannabis products. These factors will then be included in univariate and multivariate analyses as being present or absent to estimate their effect on clinical and biochemical outcomes.</p>
<p>Objective 3: To describe maternal, paternal, placental, foetal and neonatal outcomes according to the use and exposure to tobacco, nicotine and cannabis products and biochemical and genomic analysis</p>	
<p>Outcomes</p>	<p>Data and Statistical analysis</p>
<p>a) Describe maternal, placental, foetal and neonatal outcomes</p>	<p>a) Descriptive statistics of maternal, placental, foetal and neonatal outcomes will be reported including frequency, means/medians and percentages.</p>
<p>b) Determine correlations maternal, paternal, placental and neonatal outcomes and parental and foetal</p>	<p>b) Using clinical knowledge and the literature, directed acyclic graphs (DAGs) will be constructed to aid identification of causal effects/associations between 1) clinical outcomes, 2) self-reported tobacco, nicotine and cannabis use, 3) tobacco,</p>

<p>tobacco, nicotine and cannabis biochemical concentrations/pharmacokinetics.</p>	<p>nicotine and cannabis metabolite concentrations, and 4) identified biomarkers, genetic/epigenomic/germline alterations, to determine which factors to include in statistical models.</p>
<p>c) Determine correlations between maternal, paternal, placental and neonatal outcomes and genomic factors.</p>	<p>c) Multilevel regression modelling will be used to account for the clustering effect (random effects) of each individual mother, to estimate adjusted odds ratios (logistic regression for dichotomous or categorial outcomes) or beta coefficients (linear regression for continuous data outcomes) and 95% CIs for associations. A range of adjustment factors will be considered as both fixed and random effects in the models including gestational age, infant sex, birth weight, preterm delivery, delivery method, post-partum haemorrhage, preeclampsia, maternal age, height, body mass index, parity, urinary tract infection, sexually transmitted infection, diabetes, hypertension, placental data.</p>
<p>Objective 4: To describe the influences and barriers to cessation for pregnant Australian Indigenous women and their partners or close household contacts to reduce or cease tobacco and nicotine use in pregnancy</p>	
<p>Outcomes</p>	<p>Data and Statistical analysis</p>
<p>a) Qualitative exploration with information rich participants to understand the barriers and influences on tobacco, nicotine and cannabis cessation.</p> <p>b) Understand the population's health literacy and risk perception related to tobacco, nicotine and cannabis products peri-pregnancy.</p>	<p>a & b) Data will be coded and analysis will follow established processes [47] with a preliminary thematic analysis assigning meaning to the data and generating categories and subcategories. The categories most often mentioned will be identified and similarities and dissimilarities detailed. The categories will then be further grouped, and themes and subthemes identified. These will be shared with the research team for review and modification as needed. The consensus themes will be organised for analysis using NVIVO 12.</p>

527 **Ethical approval**

528 This project has been approved by the Traditional Owners of the Fraser Coast area,
529 the Butchulla people, in conjunction with Galangoor Duwalami Primary Healthcare
530 Service. The project has the support of the Queensland Aboriginal and Torres Strait
531 Islander Health Council (QAIHC) and has ethics approval from Qhealth
532 (HREC/2021/QRBW/77758) and the University of Queensland (2021/HE002069).

533

534 **Discussion**

535 The overarching vision of this clinically derived, clinically driven, community based,
536 mixed method project is to *Close the Gap* in Aboriginal and Torres Strait health
537 outcomes. This project takes a life-course epidemiological approach to health
538 outcomes, focusing on the start of life, that is, maternal and neonatal health to
539 improve whole-of-life health outcomes.

540

541 Seventy years of evidence demonstrates that maternal tobacco smoking and exposure
542 to combusted tobacco are the leading modifiable risk behaviours associated with
543 adverse pregnancy outcomes [48]. Currently in Australia, the assessment for tobacco
544 and nicotine exposure during pregnancy is focused on maternal cigarette use - no
545 information on other forms of tobacco, nicotine or cannabis use and exposure is
546 standardly collected or considered to inform clinical care. In addition, fathers or
547 other household members are not asked about their tobacco, nicotine and cannabis

548 use. This limited (or absent) tobacco, nicotine and cannabis screening fails to address
549 the broad range of contemporary products that are used in Australia and thus has
550 ramifications for the mother, the father, the children, the clinician, Indigenous
551 populations, and the broader profile of Australian health.

552

553 This project will be reported against the STOBE Guidelines and has purposeful and
554 significant objectives. Firstly, the development of a validated tobacco and nicotine
555 screening tool that can be translated to practice Australia-wide will enhance data
556 reporting and the understanding of tobacco, nicotine and cannabis use and exposure
557 to pregnancy outcomes. In addition, the use of a comprehensive and contemporary
558 screening tool will provide an opportunity for women, families and health
559 professionals to discuss tobacco, nicotine and cannabis use and reduction/cessation
560 options.

561

562 Secondly, addressing the absence of literature related to the metabolism of nicotine
563 and the influence of pharmacogenomic factors in Australian Indigenous populations
564 will be transformative. As biotechnology has evolved, there has been an increasing
565 recognition that genetics, epigenetics, and environmental interactions impact on
566 health outcomes. The role of genomics in understanding population risks and
567 targeting prevention or intervention programs to reduce risk or to provide treatment
568 based on genomic knowledge (i.e., a precision medicine approach) is of enormous
569 public health benefit. Genomic profiling allows for the understanding of different
570 outcomes in different populations from the same exposure. Already research exists

571 that shows that nicotine is metabolised differently in genetically different populations
572 [49-53] and particular risks are higher or lower in populations based on these genetic
573 differences, however, this same level of understanding has not been established for
574 Australian Indigenous parental populations. A genome-wide mapping of specific
575 biological samples from the local Australian Indigenous parental population in
576 relation to their potential risk from tobacco and nicotine use and exposure and
577 establishing [the start of] a pharmacogenomic profile will structure a precision
578 medicine approach to health care [54, 55] for this population.

579

580 Comprehension and appreciation of the barriers to tobacco, nicotine and cannabis
581 cessation is an essential mechanism in supporting the decrease in tobacco, nicotine
582 and cannabis use. Awareness these factors can lead to the construction of a range of
583 education and support resources which can be selected by future pregnant women
584 and the family to assist them to reduce or cease tobacco, nicotine and cannabis use in
585 pregnancy.

586

587 Importantly, the findings from the tobacco, nicotine and cannabis assessment and
588 analysis will be linked to maternal and neonatal outcomes. Using the screening tool
589 as part of standard practice in the future will provide a predictive methodology,
590 enabling expectant mothers, families and health services to better plan birthing and
591 post-birthing needs in situations where tobacco, nicotine and cannabis exposure is an
592 independent factor.

593

594 This research project is built on respect for the value of Indigenous perspectives and
595 their contribution to the study. Indigenous knowledge systems are incorporated into
596 the research methodology thereby mutually enriching the research. Translation to
597 practice is an intended outcome of this project but will not be structured until findings
598 are available. The intention is that translation will be informed by the Indigenous
599 participants, the Aboriginal and Torres Strait Islander health service, the research-
600 intensive organisations supporting this research and their researchers, and the chief
601 researcher.

602 **Limitations**

603 The study consists of some strengths and limitations. One significant strength is the
604 recording of tobacco, nicotine and cannabis use and exposure throughout early to late
605 pregnancy and the collection of a range of biological samples that are used to
606 measure:

- 607 • Recency of maternal tobacco and nicotine exposure (maternal CO, saliva, and
608 maternal venous blood and urine),
- 609 • The transfer of nicotine to the foetus (venous cord blood, amniotic fluid and
610 neonatal urine),
- 611 • The return of nicotine from the foetus (arterial cord blood)
- 612 • The longevity of exposure (placenta and meconium)

613

614 This approach minimises recall bias and provides a comprehensive and measurable
615 assessment of tobacco and nicotine exposure over the duration of pregnancy.

616 However, the study will only recruit mothers expecting an Australian Indigenous
617 baby in the Fraser Coast area which limits the generalizability of the findings.
618 Additionally, being an observational study, the results will not provide the strongest
619 evidence to establish a causal relationship between nicotine exposure or metabolism
620 and pregnancy outcomes.

621 **Authors contributions**

622 AR: Conceptualization, design and methodology, establish collaborations and project
623 administration, data collection, resources, writing original draft, review and editing.
624 EAB: Data curation, formal analysis, investigation, methodology, software, validation,
625 writing – review & editing. VB, JB, GM, MS: Conceptualization, supervision, writing –
626 review & editing. GD, SO: Resources, supervision, writing – review & editing. AW:
627 Conceptualization, methodology, resources, supervision, writing – review & editing.
628 SB: Conceptualization, methodology, supervision, writing – review & editing. M-TW:
629 Methodology, writing – review & editing. JM Methodology, supervision, validation,
630 writing – review & editing. KJS: Methodology, resources, supervision, validation,
631 writing – review & editing.

632

633 **Acknowledgements**

634 This project could not have developed without the overwhelming endorsement and
635 governance of the Traditional Owners of the Fraser Coast area, the Butchulla people
636 and the Butchulla Aboriginal Corporation and the Butchulla Men’s Business
637 Association. Furthermore, this project cannot progress without the consistent and

638 positive leadership of GD, SO and SB at Galangoor Duwalami Primary Healthcare
639 Service and the engaged involvement of the Galangoor Duwalami teams that wrap
640 around and support the Indigenous expectant families of the Fraser Coast area.
641 Moreover, the cooperation and involvement of maternal services and their support
642 teams from Wide Bay Hospital and Health Services Fraser Coast is essential in
643 ensuring this collaborative project can achieve its aim. Fraser Coast Sullivan and
644 Nicolaides Pathology service are sentinel in the transport of biological samples to
645 Brisbane and the University of Queensland and are providing this service pro bono.
646 In terms of the design, AR conceived, designed the framework of the study, and will
647 lead the data collection. AW, GM, VB, JB and MS guided the data collection design with
648 Indigenous mothers and families and consulted with their respective Indigenous
649 organisations and community members to ensure cultural and community safety and
650 expectations were established. LB designed the statistical analysis and will undertake
651 the data analysis. M-TW will undertake the biochemical analysis as a PhD Scholar at
652 the University of Queensland under the supervision of JM and KS. AR is partially
653 funded under a QHealth Advancing Clinical Research Fellowship.

654

655 **Conflicts of Interest**

656 None declared.

657 **Abbreviations**

658 ADHD – attention-deficit/hyperactivity disorder

659 CO - carbon monoxide

660 DAGs - directed acyclic graphs

661 mRNA - messenger ribonucleic acid

662 nAChR - nicotinic acetylcholine receptors

663 NMR - nicotine metabolite ratio

664 NRT - nicotine replacement therapy

665 POC - point of care

666 QAIHC - Queensland Aboriginal and Torres Strait Islander Health Council

667 NOTICE - Ratsch Assessment of Tobacco and Nicotine

668 SIDS - sudden infant death syndrome

669 SNPs - single nucleotide polymorphisms

670 TNE - total nicotine equivalents

671

672

673 **Supporting Information.** Supplementary Table 1: Variables of interest for analysis

674 extracted from standard National Perinatal Data Collection report, together with

675 variables of interest for this project (i.e., tobacco, nicotine and cannabis use and

676 exposure)

677

678 **References**


679

- 680 1. Simpson WJ. A preliminary report on cigarette smoking and the incidence of
681 prematurity. *Am J Obstet Gynecol.* 1957;73(4):807-15.
- 682 2. Avsar TS, McLeod H, Jackson L. Health outcomes of smoking during
683 pregnancy and the postpartum period: an umbrella review. *BMC Pregnancy*
684 *Childbirth.* 2021;21(1):254.
- 685 3. Naeye RL. Abruptio placentae and placenta previa: frequency, perinatal
686 mortality, and cigarette smoking. *Obstet Gynecol.* 1980;55(6):701-4.
- 687 4. Marcoux S, Brisson J, Fabia J. The effect of cigarette smoking on the risk of
688 preeclampsia and gestational hypertension. *Am J Epidemiol.* 1989;130(5):950-7.
- 689 5. England LJ, Levine RJ, Qian C, Morris CD, Sibai BM, Catalano PM, et al.
690 Smoking before pregnancy and risk of gestational hypertension and preeclampsia.
691 *Am J Obstet Gynecol.* 2002;186(5):1035-40.
- 692 6. Gould GS, Havard A, Lim LL, The Psanz Smoking In Pregnancy Expert G,
693 Kumar R. Exposure to Tobacco, Environmental Tobacco Smoke and Nicotine in
694 Pregnancy: A Pragmatic Overview of Reviews of Maternal and Child Outcomes,
695 Effectiveness of Interventions and Barriers and Facilitators to Quitting. *Int J Environ*
696 *Res Public Health.* 2020;17(6).
- 697 7. Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth
698 defects: a systematic review based on 173 687 malformed cases and 11.7 million
699 controls. *Hum Reprod Update.* 2011;17(5):589-604.
- 700 8. Yang L, Wang H, Yang L, Zhao M, Guo Y, Bovet P, et al. Maternal cigarette
701 smoking before or during pregnancy increases the risk of birth congenital
702 anomalies: a population-based retrospective cohort study of 12 million mother-
703 infant pairs. *BMC Med.* 2022;20(1):4.
- 704 9. Clifford A, Lang L, Chen R. Effects of maternal cigarette smoking during
705 pregnancy on cognitive parameters of children and young adults: a literature
706 review. *Neurotoxicol Teratol.* 2012;34(6):560-70.
- 707 10. Sourander A, Sucksdorff M, Chudal R, Surcel HM, Hinkka-Yli-Salomaki S,
708 Gyllenberg D, et al. Prenatal Cotinine Levels and ADHD Among Offspring. *Pediatrics.*
709 2019;143(3).
- 710 11. Australian Institute of Health and Welfare. [Internet]. Canberra: National
711 Perinatal Data Collection (NPDC): Australian Government; 2020 [cited 2024 3
712 January]. Available from: [https://www.aihw.gov.au/about-our-data/our-data-](https://www.aihw.gov.au/about-our-data/our-data-collections/national-perinatal-data-collection)
713 [collections/national-perinatal-data-collection](https://www.aihw.gov.au/about-our-data/our-data-collections/national-perinatal-data-collection).
- 714 12. Australian Institute of Health and Welfare. [Internet]. Australia's mothers
715 and babies; 2023 [cited 2024 3 January]. Available from:
716 [https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-](https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies/contents/about)
717 [babies/contents/about](https://www.aihw.gov.au/reports/mothers-babies/australias-mothers-babies/contents/about).
- 718 13. Australian Institute of Health and Welfare, National Indigenous Australian
719 Agency. [Internet]. Canberra: Tier 2 Determinants of health 2.21 Health behaviours
720 during pregnancy: Australian Government; 2022 [cited 2024 5 January]. Available
721 from: [https://www.indigenoushpf.gov.au/measures/2-21-health-behaviours-](https://www.indigenoushpf.gov.au/measures/2-21-health-behaviours-during-pregnancy)
722 [during-pregnancy](https://www.indigenoushpf.gov.au/measures/2-21-health-behaviours-during-pregnancy).

- 723 14. Australian Institute of Health and Welfare. [Internet]. Canberra: Pregnancy
724 and birth outcomes for Aboriginal and Torres Strait Islander women 2016–2018.
725 Cat. no. IHW 234: AIHW; 2021 [cited 2023 14 October]. Available from:
726 [https://www.aihw.gov.au/reports/indigenous-australians/pregnancy-birth-](https://www.aihw.gov.au/reports/indigenous-australians/pregnancy-birth-outcomes-indigenous-women-2016-18/contents/summary)
727 [outcomes-indigenous-women-2016-18/contents/summary](https://www.aihw.gov.au/reports/indigenous-australians/pregnancy-birth-outcomes-indigenous-women-2016-18/contents/summary).
728 15. Australian Institute of Health and Welfare. [Internet]. Canberra: Stillbirths
729 and neonatal deaths in Australia 2017 and 2018: AIHW; 2021 [cited 2024 24
730 January]. Available from: [https://www.aihw.gov.au/getmedia/4b6ff4e5-f549-42c7-](https://www.aihw.gov.au/getmedia/4b6ff4e5-f549-42c7-96ac-e6cc221d79b8/aihw-per-115.pdf.aspx)
731 [96ac-e6cc221d79b8/aihw-per-115.pdf.aspx](https://www.aihw.gov.au/getmedia/4b6ff4e5-f549-42c7-96ac-e6cc221d79b8/aihw-per-115.pdf.aspx).
732 16. Benowitz NL, Hukkanen J, Jacob P, III. Nicotine Chemistry, Metabolism,
733 Kinetics and Biomarkers. In: Henningfield JE, London ED, Pogun S, editors. Nicotine
734 Psychopharmacology. Handbook of Experimental Pharmacology. 192: Springer
735 Berlin Heidelberg; 2009. p. 29-60.
736 17. McGrath-Morrow SA, Gorzkowski J, Groner JA, Rule AM, Wilson K, Tanski SE,
737 et al. The Effects of Nicotine on Development. *Pediatrics*. 2020;145(3).
738 18. Hukkanen J, Jacob P, 3rd, Benowitz NL. Metabolism and disposition kinetics
739 of nicotine. *Pharmacol Rev*. 2005;57(1):79-115.
740 19. Tizabi Y, Getachew B, Copeland RL, Aschner M. Nicotine and the nicotinic
741 cholinergic system in COVID-19. *FEBS J*. 2020;287(17):3656-63.
742 20. Banerjee S, Deacon A, Suter MA, Aagaard KM. Understanding the Placental
743 Biology of Tobacco Smoke, Nicotine, and Marijuana (THC) Exposures During
744 Pregnancy. *Clin Obstet Gynecol*. 2022;65(2):347-59.
745 21. Pintican D, Poienar AA, Strilciuc S, Miha D. Effects of maternal smoking on
746 human placental vascularization: A systematic review. *Taiwan J Obstet Gynecol*.
747 2019;58(4):454-9.
748 22. Beltrán-Castillo S, Bravo K, Eugén J. Impact of Prenatal Nicotine Exposure
749 on Placental Function and Respiratory Neural Network Development. In: Gonzalez-
750 Ortiz M, editor. *Advances in Maternal-Fetal Biomedicine: Cellular and Molecular*
751 *Mechanisms of Pregnancy Pathologies*. Cham: Springer International Publishing;
752 2023. p. 233-44.
753 23. Alzu'bi A, Middleham W, Shoaib M, Clowry GJ. Selective Expression of
754 Nicotinic Receptor Sub-unit mRNA in Early Human Fetal Forebrain. *Front Mol*
755 *Neurosci*. 2020;13:72.
756 24. National Research Council (US) and Institute of Medicine (US) Committee on
757 Integrating the Science of Early Childhood Development. [Internet]. Washington
758 (DC): From Neurons to Neighborhoods: The Science of Early Childhood
759 Development. *The Developing Brain: National Academies Press* 2000 [cited 2024 29
760 January]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK225562/>.
761 25. Slotkin TA. If nicotine is a developmental neurotoxicant in animal studies,
762 dare we recommend nicotine replacement therapy in pregnant women and
763 adolescents? *Neurotoxicol Teratol*. 2008;30(1):1-19.
764 26. Buck JM, O'Neill HC, Stitzel JA. Developmental nicotine exposure elicits
765 multigenerational disequilibria in proBDNF proteolysis and glucocorticoid signaling
766 in the frontal cortices, striata, and hippocampi of adolescent mice. *Biochem*
767 *Pharmacol*. 2019;168:438-51.

- 768 27. Bednarczuk N, Milner A, Greenough A. The Role of Maternal Smoking in
769 Sudden Fetal and Infant Death Pathogenesis. *Front Neurol.* 2020;11:586068.
- 770 28. Benowitz NL. Clinical pharmacology of nicotine. *Annu Rev Med.* 1986;37:21-
771 32.
- 772 29. Benowitz NL, Kuyt F, Jacob P, 3rd, Jones RT, Osman AL. Cotinine disposition
773 and effects. *Clin Pharmacol Ther.* 1983;34(5):604-11.
- 774 30. Benowitz NL, Dains KM, Dempsey D, Yu L, Jacob P, 3rd. Estimation of nicotine
775 dose after low-level exposure using plasma and urine nicotine metabolites. *Cancer*
776 *Epidemiol Biomarkers Prev.* 2010;19(5):1160-6.
- 777 31. Dempsey D, Jacob P, 3rd, Benowitz NL. Accelerated metabolism of nicotine
778 and cotinine in pregnant smokers. *J Pharmacol Exp Ther.* 2002;301(2):594-8.
- 779 32. Arger CA, Taghavi T, Heil SH, Skelly J, Tyndale RF, Higgins ST. Pregnancy-
780 Induced Increases in the Nicotine Metabolite Ratio: Examining Changes During
781 Antepartum and Postpartum. *Nicotine Tob Res.* 2019;21(12):1706-10.
- 782 33. Dempsey D, Jacob P, 3rd, Benowitz NL. Nicotine metabolism and elimination
783 kinetics in newborns. *Clin Pharmacol Ther.* 2000;67(5):458-65.
- 784 34. Feyerabend C, Russell MAH. Effect of urinary pH and nicotine excretion rate
785 on plasma nicotine during cigarette smoking and chewing nicotine gum. *Br J Clin*
786 *Pharmacol.* 1978;5(4):293-7.
- 787 35. Taghavi T, Arger CA, Heil SH, Higgins ST, Tyndale RF. Longitudinal Influence
788 of Pregnancy on Nicotine Metabolic Pathways. *Journal of Pharmacology and*
789 *Experimental Therapeutics.* 2018;364(2):238-45.
- 790 36. The National Health and Medical Research Council, the Australian Research
791 Council, and Universities Australia. National Statement on Ethical Conduct in Human
792 Research 2007 (Updated 2018). Canberra: Commonwealth of Australia; 2018.
- 793 37. Geia LK, Hayes B, Usher K. Yarning/Aboriginal storytelling: towards an
794 understanding of an Indigenous perspective and its implications for research
795 practice. *Contemp Nurse.* 2013;46(1):13-7.
- 796 38. Bessarab D, Ng'andu B. Yarning About Yarning as a Legitimate Method in
797 Indigenous Research. *International Journal of Critical Indigenous Studies.*
798 2010;3(1):37-50.
- 799 39. Walker M, Fredericks B, Mills K, Anderson D. "Yarning" as a method for
800 community-based health research with Indigenous women: the Indigenous
801 Women's Wellness Research Program. *Health Care Women Int.* 2014;35(10):1216-
802 26.
- 803 40. Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, Jarvis MJ, et al.
804 Biochemical Verification of Tobacco Use and Abstinence: 2019 Update. *Nicotine Tob*
805 *Res.* 2020;22(7):1086-97.
- 806 41. Benowitz NL, St Helen G, Nardone N, Cox LS, Jacob P. Urine Metabolites for
807 Estimating Daily Intake of Nicotine From Cigarette Smoking. *Nicotine Tob Res.*
808 2020;22(2):288-92.
- 809 42. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P, III. Nicotine metabolite
810 ratio as a predictor of cigarette consumption. *Nicotine Tobacco Res.* 2003;5(5):621-
811 4.

- 812 43. Gilligan C, Sanson-Fisher R, Eades S, Wenitong M, Panaretto K, D'Este C.
813 Assessing the accuracy of self-reported smoking status and impact of passive smoke
814 exposure among pregnant Aboriginal and Torres Strait Islander women using
815 cotinine biochemical validation. *Drug Alcohol Rev.* 2010;29(1):35-40.
- 816 44. Malhotra RK, Indrayan A. A simple nomogram for sample size for estimating
817 sensitivity and specificity of medical tests. *Indian J Ophthalmol.* 2010;58(6):519-22.
- 818 45. McNeish DM. Modeling sparsely clustered data: design-based, model-based,
819 and single-level methods. *Psychol Methods.* 2014;19(4):552-63.
- 820 46. Vaz LR, Coleman T, Cooper S, Aveyard P, Leonardi-Bee J, team St. The
821 Nicotine Metabolite Ratio in Pregnancy Measured by trans-3'-Hydroxycotinine to
822 Cotinine Ratio: Characteristics and Relationship With Smoking Cessation. *Nicotine
823 Tob Res.* 2015;17(11):1318-23.
- 824 47. Braun V, Clarke V. Using thematic analysis in psychology. *Qualitative
825 Research in Psychology.* 2006;3(2):77-101.
- 826 48. National Center for Chronic Disease Prevention and Health Promotion (US)
827 Office on Smoking and Health. Reproductive Outcomes. *The Health Consequences of
828 Smoking—50 Years of Progress: A Report of the Surgeon General.* Atlanta (GA):
829 Centers for Disease Control and Prevention (US); 2014. p. 461-521.
- 830 49. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P, 3rd. Slower metabolism and
831 reduced intake of nicotine from cigarette smoking in Chinese-Americans. *J Natl
832 Cancer Inst.* 2002;94(2):108-15.
- 833 50. Cecil CA, Walton E, Smith RG, Viding E, McCrory EJ, Relton CL, et al. DNA
834 methylation and substance-use risk: a prospective, genome-wide study spanning
835 gestation to adolescence. *Transl Psychiatry.* 2016;6(12):e976.
- 836 51. Chen X, Woodcroft KJ. Polymorphisms in metabolic genes CYP1A1 and
837 GSTM1 and changes in maternal smoking during pregnancy. *Nicotine Tob Res.*
838 2009;11(3):225-33.
- 839 52. Keskitalo K, Broms U, Heliovaara M, Ripatti S, Surakka I, Perola M, et al.
840 Association of serum cotinine level with a cluster of three nicotinic acetylcholine
841 receptor genes (CHRNA3/CHRNA5/CHRNA4) on chromosome 15. *Hum Mol Genet.*
842 2009;18(20):4007-12.
- 843 53. Marceau K, Palmer RH, Neiderhiser JM, Smith TF, McGuey JE, Knopik VS.
844 Passive rGE or developmental gene-environment cascade? An investigation of the
845 role of xenobiotic metabolism genes in the association between smoke exposure
846 during pregnancy and child birth weight. *Behav Genet.* 2016;46(3):365-77.
- 847 54. Allenby CE, Boylan KA, Lerman C, Falcone M. Precision Medicine for Tobacco
848 Dependence: Development and Validation of the Nicotine Metabolite Ratio. *J
849 Neuroimmune Pharmacol.* 2016;11(3):471-83.
- 850 55. Cheng YY, Nunn J, Skinner J, Rambaldini B, Boughtwood T, Calma T, et al. A
851 Pathway to Precision Medicine for Aboriginal Australians: A Study Protocol.
852 *Methods Protoc.* 2021;4(2):42.
853



Project logo



Participant polo



Participant Onesie

NicOTIne, tobacco and Cannabis use and Exposure (NOTICE) assessment tool

To calculate self-use (SU) score:

Self-Use score calculated for each **weekly** product.

Quantity reported	Use	Score
0	None	0
1 - 70	Low	1
71 - 140	Medium	2
141 +	High	3

Total self-use score = sum of all weekly self-use scores.

To calculate total exposure (E) score:

Exposure score calculated for each **weekly** product exposed to.

Quantity	Exposure	Quantity Score
0	None	0
1 - 70	Low	1
71 - 140	Medium	2
141 +	High	3

Exposure	Exposure
0	No known exposure
1	Some limited exposure, e.g. outdoor
2	Moderate exposure, e.g. indoor but restricted to certain areas
3	No restriction, e.g. full exposure in the house, in bedroom or car.

Exposure score = weekly quantity score x weekly exposure score (range 0 – 9)

Total exposure score = sum of all exposure scores.